FDA Approves Pembrolizumab/Axitinib Combo for Frontline RCC

April 22, 2019 – The FDA has approved pembrolizumab in combination with axitinib for the frontline treatment of patients with advanced renal cell carcinoma (RCC). The approval is based on findings from the phase III KEYNOTE-426 trial, which demonstrated that the frontline combination significantly improved overall response rates (ORRs), progression-free, and overall survival (OS) compared with sunitinib in patients with advanced RCC. Moreover, data … (leggi tutto)